EPO DTC Ads Create Impression Unsupported By Data, FDA And ODAC Agree
Executive Summary
FDA and the experts on its Oncologic Drugs Advisory Committee alike have been troubled by the way that unchecked direct-to-consumer advertising of erythropoiesis-stimulating agents has created a favorable impression of the anemia therapies that is not supported by available data